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Phencyclidine was determined by gas chromatography selected ion monitoring in six dogs and seven monkeys. 
Aliquots of venous blood were taken over 4 h in the monkey after 1.1 mg kg-' and over 24 h in the dog after 
1.0mgkg-' of phencyclidine i.v. Pentadeuterated phencyclidine was used as the internal standard. In the 
electron impact mode the most abundant fragments in the mass specbum of phencyclidine were m/e 91 and 
200, and 96 and 205 in the [ZH,]phencyclidine spectrum. These fragments were used to quantitate the amount 
of phencyclidine present. In both species, a complex exponential decline of plasma phencyclidine was found in 
most animals that fit a two compartment open model. In monkeys, the mean half-life (B phase) was 2.36 h and 
in the dog it was 2.86 h. Compared with the monkey, the dog exhibited considerable emergence delirium. The 
two species had rather different pharmacokinetics which may be relevant to the observed differences in degree 
of anesthesia and recovery. 
INTRODUCTION 
In recent years the need to identify phencyclidine [PCP, 
1-(1-phenylcyclohexyl) piperidine] in biological fluids 
and tissues has become important. This drug is increas- 
ingly abused. A number of clinical reports on human 
overdose cases have appeared.'-' Previous means of 
detection of PCP by chromatography and 
fluorometry6" are not specific. Gas chromatography 
mass spectrometry has done much to advance our 
knowledge in this Since PCP undergoes 
thermal decomposition above temperatures of 150 "C 
to form l-phenyl-cyclohexene,11'12 temperatures in all 
phases of the experiment must be carefully controlled. 
A number of  investigator^"-'^ have reported quan- 
titative GCMS assays for PCP. We have adapted the 
GCMS chemical ionization (methane) assay of Lin et 
al.'* for electron impact (EI). We have used G C  selec- 
ted ion monitoring to assay PCP in the plasma of the 
dog and monkey and have determined its plasma 
pharmacokinetics as described in this report. 
EXPERIMENTAL 
Animals 
Six mongrel dogs of either sex were fasted 12 h prior to 
being given 1.0mg kg-' PCP HCl i.v. calculated as 
t Preliminary paper presented before the American Society for 
Pharmacology and Experimental Therapeutics: A. E. Wilson and E. 
F. Domino, Pharmacologist 18, 142 (1976). 
f PCP = phencyclidine; ['H,]PCP = pentadeuterated phencyclidine 
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base. Control bloods were taken prior to the injection 
of PCP. Blood was collected from an indwelling venous 
cannula for 24 h during which time the dogs were 
allowed complete freedom of movement. PCP was 
given over a 1 min period. 
Seven former morphine dependent Macaca mulatta 
monkeys of either sex were used in these experiments. 
At the time they were given PCP they had completely 
recovered from their narcotic dependence for 3-6 
months. These animals were not on any medication. 
The animals were given 1.1 mg kg-' of PCP HCI i.v. 
over 1 min with the dose calculated as base. Venous 
blood samples were collected over a 4 h period from an 
indwelling venous catheter. In both groups of animals 
all blood removed was replaced by an equal volume of 
0.9% NaCI. Whole blood was collected in heparinized 
tubes, spun at 1OOOg for 15min and the plasma 
removed for PCP extraction. 
Assay 
The method of Lin et aL'* was used to extract PCP. 
Briefly this involves adding 1 p g  of pentadeuterated i PCP ([ H5] PCP) to the sample, buffering to pH 9.5 and 
extracting twice with hexane. A back extraction was 
done into 0.2NH2S04.  After removal of the organic 
layer, the aqueous phase was buffered to pH9.5 for a 
final extraction into hexane. The hexane layer was 
removed and evaporated to dryness. One to 2 p1 of the 
reconstituted sample in 25 pl  of hexane was used for 
GCMS analysis. In this study a Finnigan 3200 
quadrapole gas chromatograph mass spectrometer with 
a 6102 data system was used in the EI mode. The GC 
conditions were with a column temperature of 190°C 
and injection port of 200°C to minimize thermal 
decomposition of PCP. Helium flow was 20 ml min-'. 
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A 5 ft x 2 mm glass column was packed with 2.5% SE- 
30 on Chromasorb G or 3% OV-17 on Gas Chrom Q. 
Two different columns were used since the OV-17 
column separated a small interfering peak in recording 
m/e 200 in the selected ion profile of the monkey 
plasma. The glass jet separator was at 210 "C to prevent 
sample condensation in the jet tip. All other lines were 
glass lined. The fragments were produced by EI at 
70 eV. 
Pharmacokinetic analysis 
The number of compartments in an open compartment 
model was determined by an Amdahl 47$V/C 
computer using the method of Wagner et al. The 
exponential equation to describe a multicompartment 
model was 
c = A e - a t + B e - o t + .  . . 
where C is the concentration at any time, t ,  A and B 
are constants for each compartment of which LY and p 
are exponents. A two compartment open model is 
shown below in which the phencyclidine was intro- 
duced directly into the plasma compartment: 
Drug at site K~ Drug in plasma Kz Drug 
of administration A compartment eliminated 
Drug in tissues 
B compartment 
The parameters A ,  B and a,@ were determined by a 
curve stripping program and Co, K2,  Kz l  and K l z  were 
found by a nonlinear regression program [Wagner, 
personal communication (1977)l. The rate constants of 
the model were calculated as K2 = ~ / ( A ' / L Y  + B ' / P )  
KZ1 =Alp  +?'a, K I 2 = A ' B '  ( P - L Y ) ~ / K ~ ~  where A ' =  
A / A  + B and B' = B / A  + B. 
----+ + 
K12 J r K21 
RESULTS 
The combination of GCMS in the selected ion moni- 
toring mode gives a very sensitive and quantitative 
means for determining PCP. With the use of [2HS]PCP 
as the internal standard, other possible drugs and 
materials found in biological samples can be avoided. 
In Fig. 1 is illustrated a total ion chromatogram (TIC) 
of 1 pg of PCP and C2H5]PCP each added to monkey 
plasma. Since the final amount is concentrated in 20- 
25 p1 of hexane, these peaks represent 40-50 ng when 
1 pl is injected. The mass spectra of PCP and ['Hs]PCP 
are illustrated in Fig. 2. Note the molecular ions 
m/e 243 and m/e 248 are present but are of relatively 
low intensity as if often true of EI produced spectra. 
The base peak of PCP is m/e 200 and 205 for 
[2H5]PCP. In view of the fact that m/e 91, 96,200 and 
205 represent the major fragments of both PCP and 
[2Hs]PCP, these were monitored to obtain a standard 
calibration curve. The m/e 91,96 peak area ratios were 
monitored as a qualitative check for PCP while m/e 
200, 205 peak area ratios were used to determine the 
amount of PCP present. With this method of ex- 
too I00 
50 100 50 100 
Scan number 
Figure 1. Total ion chromatogram of (a) phencyclidine and (b) 
['H51phencyclidine. PCP and ['H51PCP (1 pg  mi-') were run 
separately under the conditions listed. ['H51PCP has a slightly 
shorter retention time, indicating an isotope effect. Conditions 
were as follows: Col. = 3% OV-17; Sol. = hexane; Col. temp. = 
190°C; Sep. temp.=210"C; Heflow=20ccmin-'. 
{ , 1 Yol.rt=243.38 I 
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Figure 2. Mass spectra of (a) phencyclidine and (b) ['H5]phen- 
cyclidine. Note that the major ions of PCP, m/e 91,200 and 243, 
are 5 mle higher for ['H5]PCP. 
traction, PCP metabolites are not extracted. Their 
retention times are also known to be different from that 
A typical mass fragmentogram is illustrated in Fig. 3. 
It can be noted that there are no interfering 
constituents in the plasma sample. With a TIC 100 ng 
was the limit of detectability; in selected ion monitoring 
5 ng could be easily detected. A standard curve for PCP 
in dog and monkey plasma is shown in Fig. 4. Deter- 
minations were done to 0.1 ng; however, they are not 
indicated on the graph. The peak area ratio of 200/205 
was used to quantitate the amount of PCP present. A 
recovery check was done by splitting six samples with 
an unknown endogenous amount of PCP and adding a 
known amount of PCP to one-half of each sample in 
addition to 1 pg of [2Hs]PCP. The amount of exo- 
genous PCP added to each half was calculated as 
of PCP.I2 
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Figure 3. Selected ion profile of phencyclidine from monkey 
plasma using [2H5]phencyclidine as the internal standard. This is 
a typical run on a monkey plasma sample in which slightly less 
PCP is present than the ['H51 internal standard. 
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Figure 4. Standard calibration for phencyclidine in dog and 
monkey plasma using El selected ion monitoring. Note linearity 
of increasing amounts of PCP added to the plasma samples with 
['H5]PCP constant at 1000 ng. Approximately 1/20 (1 PI) of the 
final volume was injected into the gas chromatograph mass 
spectrometer. The x-axis represents added standards in 1 ml. 
recovery and found to be 96.6%. All samples were run 
two to three times and never varied more than *6% 
from the mean. Plasma samples determined from the 
calibration curve had a SEk 5% or less. 
The plasma concentration of six dogs given 
1.0 mg kg-I of PCP i.v. is illustrated in Fig. 5. Mean 
*SE, plasma levels of 85.90 ng ml-' f 10.8 were found 
30-45 min later when the dogs tried to lift their heads 
as a sign of partial recovery from anesthesia. While 
anesthetized, the dogs exhibited nystagmus, salivation, 
analgesia and pupillary dilatation. An emergence 
delirum of varying intensity was noted subsequently. 
This began approximately 45 min after injection and 
lasted up to 3 h with corresponding mean k SE plasma 
0.08 0.5 I 2 3 4 5 6 7 €  
Time ( h  1 
0.3 
Figure 5. Dog plasma phencyclidine concentration-time 
course. PCP was given in a dose of 1 .O mg kg-' i.v. to six dogs. 
Each symbol represents the plasma PCP level of a different 
animal over an 8 h period. 
PCP levels of 61.6k7.2 and 35.1*2.7 ngml-' respec- 
tively. 
The plasma levels of PCP in individual monkeys 
given 1.1 mg kg-' of PCP i.v. are shown in Fig. 6. At 
approximately 1 h, monkeys became conscious with 
mean *SE plasma levels of 110.0zt6.3 ngml-'. The 
monkeys recovered over the next 3 h but did not show 
any emergence delirium in contrast to the dogs. The 
dogs were fully recov7red by 8 h at which time levels 
were 18.8 f 2.8 ng ml- . No PCP was detectable in dog 
plasma 24 h after injection. 
Figure 7 and 8 represent the computer printouts for a 
two compartment model of the mean data for the six 
dogs and monkeys, respectively. Note that the 
predicted and observed points are very similar. The 
equations for each are given on the figures. The plasma 
PCP pharmacokinetic analysis of the individual animals 
and the group means are given in Table 1 for the dog 
(8 h data) and Table 2 for the monkey (4 h data). The 
SD and 95% confidence limits are indicated. 
Although the monkeys received 10% more PCP, 
their plasma levels are much higher than expected. Part 
of this may be explained by the following. The mean 
body weight of the seven monkeys was 4.87 kg. The 
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Figure 7. Computer plot of observed and predicted mean 
plasma levels of phencyclidine in the dog. The plasma con- 
centration is plotted over an 8 h interval following a dose of 
1.0 mg kg-', i.v. 
mean body weight of the five dogs with complete 
pharmacokinetic data was 18.96 kg. The apparent 
volume of distribution was calculated as 
C,,, * , - a ,  = 177.89e-"" + 146.55e-03" 
..... pt,,, = 2.26 
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Figure 8. Computer plot of observed and predicted mean 
plasma levels of phencyclidine in the monkey. The plasma 
concentration is plotted over a 4 h interval following a dose of 
1.1 mg kg-l, i.v. 
If we use the computer estimated mean for each 
compartment then the monkey has a mean central 
volume of distribution 16.5 1 compared with 35.2 1 in 
the dog. The mean volume of the peripheral compart- 
ment in the monkey was 12.1 1 compared with 99.2 1 in 
the dog. In the monkey K Z I  and Klz are very similar, 
Table 1. Pharmacokinetic parameters of phencyclidine in the dog 
c Dog Ab B a P co 
1 332.62 84.20 9.630 0.270 442.38 
2 226.62 63.15 4.957 0.136 292.69 
3 338.46 74.15 17.622 0.355 319.38 
5 178.77 123.24 1.895 0.234 281.79 
6 775.91 85.29 23.830 0.402 807.10 
Mean 370.42 86.01 11.588 0.279 428.67 
f SD 236.83 22.65 9.059 0.104 221.02 
Computerestimated mean 436.97 101.31 12.880 0.326 458.09 
- - 201.52 
a The data of dog # 4  are partially missing and were excluded from analysis. 
*Confidence limits - - 
A, B and Co are ng T I - ' .  
All rate constants h- . 
r = correlation coefficient. 
K21 
2.156 
1.037 
4.100 
0.706 
3.137 
2.227 
1.420 
3.104 
2.306 
K2 
1.207 
0.651 
1.524 
0.628 
3.052 
1.41 2 
0.992 
1,350 
0.826 
K12 
6.569 
3.405 
12.352 
0.795 
18.050 
8.234 
6.977 
8.748 
7.737 
t1/2 ( h )  
a P 
0.072 2.57 
0.140 5.10 
0.039 1.95 
0.366 2.96 
0.029 1.72 
0.129 2.86 
0.139 1.35 
0.054 2.13 
- - 
rd 
0.994 
0.997 
0.985 
0.976 
0.997 
0.990 
0.009 
0.994 - 
Table 2. Pharmacokinetic parameters of phencyclidine in the monkey" 
Monkey Ab B c a P P 1112 (h) 
d 4 CO K21 KZ K12 
1 96.34 204.80 2.753 0.330 296.16 1.962 0.463 0.658 0.252 2.10 0.980 
2 153.28 127.78 23.844 0.408 276.62 11.075 0.878 12.299 0.029 1.70 0.995 
3 342.58 - 1.108 - 373.50 - 1.108 - 0.625 - 0.957 
4 110.61 149.57 1.638 0.358 259.30 1.070 0.547 0.378 0.423 1.94 0.992 
5 116.08 133.88 1.764 0.274 302.02 0.856 0.563 0.618 0.393 2.53 0.998 
6 246.95 104.73 4.270 0.184 325.12 1.429 0.550 2.475 0.162 3.77 0.999 
7 172.55 157.58 3.257 0.326 338.06 1.613 0.657 1.312 0.213 2.13 0.999 
Mean 184.05 146.37 5.519 0.313 310.11 3.001 0.681 2.957 0.300 2.36 0.989 
*SD 85.22 34.01 8.152 0.077 38.70 3.970 0.231 4.640 0.201 0.74 0.015 
Computer estimated mean 177.89 146.55 2.677 0.307 297.12 1.379 0.591 1.013 0.259 2.26 0.995 
a The data of monkey # 3  are partially missing and hence not included. 
bA, B and Co are ng T I - ' .  
All rate constants h- . 
r = correlation coefficient. 
*Confidence limits - - - - 104.70 0.381 0.382 1.789 - - - 
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while in the dog KI2 appears larger than Kzl. The dog 
has a higher excretion rate constant. Both species have 
similar plasma half-Wes in the /3 phase. 
It should be pointed out that volumes of distribution 
are mathematical artifacts that usually are referred to 
should also be tested by varying the dose administered. 
The methods employed herein do indicate the remark- 
able utility of GCMS techniques in analyzing this 
problem further. 
as ‘apparent’ or ‘effective’ volumes to-indicate this fact 
and to emphasize they have no anatomical 
significance. Furthermore, a comparison of clearances The authors wish to thank Drs D. Lin and R. Foltz of the Battelle 
orphencyclidine in the two species would be meaning- 
ful. Obviously, further analysis of the plasma p h a -  
macokinetics of PCP are indicated with earlier and 
more frequent time points in both Species. The rdi-  
Institute, Columbus, Ohio for the pentadeuterated phencyclidine. 
Phencyclidine HCI (batch #277239) was obtained from Dr D. 
McCarthy of Parke Davis and Company, Ann Arbor, Michigan 
48106, We also wish to thank Dr Wagner of the University of 
Michigan. Ann Arbor. Michigan 48109 whose uharmacokinetic pro- 
V I  
ability of* the first order multicompartmental model grams Automan and Nonlin \;ere invaluable. 
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